Dr. Reddy’s Laboratories has delivered a mixed bag of results for the third quarter, demonstrating resilience in the face of challenges. The company reported a net profit of ₹1,209 crore, surpassing analyst expectations, although it faced year-on-year declines in both profit and EBITDA. Revenue growth showed promise with a 4.4% increase, highlighting a complex financial landscape shaped by various market dynamics.
Financial Overview
For the third quarter, Dr. Reddy’s net profit of ₹1,209 crore exceeded the estimate of ₹1,132 crore predicted by analysts. Revenue for the quarter reached ₹8,753 crore, significantly above the forecast of ₹8,273 crore. Similarly, EBITDA came in at ₹1,887.4 crore, surpassing expectations of ₹1,803 crore, while the EBITDA margin stood at 21.5%, slightly below the anticipated 21.80%.
However, a closer look reveals a 14.5% decline in net profit compared to ₹1,413 crore in the same quarter last year. While revenue increased from ₹8,381 crore, EBITDA experienced a notable drop of 17% from the previous year’s figure of ₹2,273 crore. The contraction in margins was significant, with the EBITDA margin falling from 27.1% to 21.5% year-on-year.
Segment Performance Analysis
In the first nine months of FY26, consolidated revenues reached ₹26,080 crore, reflecting an 8% year-on-year growth. This performance was driven by broad-based growth across key markets, except for the North American generics segment, which suffered from reduced lenalidomide sales. Additionally, favorable foreign exchange movements contributed positively to the overall performance.
Global generics revenues for the third quarter were ₹7,910 crore, marking a 7% year-on-year growth and a 1% increase quarter-on-quarter. Over the nine-month period, global generics revenues rose by 9% year-on-year to ₹23,320 crore.
North American Market Challenges
The North American market presented challenges during Q3FY26, with revenues declining to ₹2,960 crore, down 12% year-on-year and 9% sequentially. For the nine-month period, revenues dropped by 12% year-on-year to ₹9,620 crore. The decline was primarily attributed to lower lenalidomide sales, coupled with price erosion in several key products.
Despite these setbacks, Dr. Reddy’s launched six new products in the third quarter, bringing the total number of launches to 18 for the first nine months of the fiscal year. The company filed four new Abbreviated New Drug Applications (ANDAs) with the US FDA, contributing to a total of 10 filings for the nine-month period. As of December 31, 2025, the company had 73 filings awaiting FDA approval.
European Market Growth
Conversely, the European market showed promising growth, with revenues in Q3FY26 rising by 20% year-on-year and 5% quarter-on-quarter to reach ₹4,450 crore. For the nine-month period, revenues surged 77% year-on-year to ₹4,100 crore. Excluding the NRT portfolio, growth in Europe was a substantial 16% year-on-year. This performance was bolstered by new generic launches and favorable foreign exchange rates, even as the company faced pricing pressures.
NRT revenues for Q3FY26 were impressive, standing at ₹1,500 crore, reflecting a 25% increase year-on-year and an 8% increase sequentially. In Germany, revenues rose by 21% year-on-year to ₹400 crore, while UK revenues saw a decline of 12% year-on-year to ₹270 crore, though they grew by 6% sequentially. The rest of Europe experienced a remarkable 49% year-on-year revenue increase in Q3FY26, totaling ₹330 crore.
Performance in Domestic and Emerging Markets
In India, Dr. Reddy’s revenues for Q3FY26 were ₹1,600 crore, an increase of 19% year-on-year and 2% quarter-on-quarter. For the nine-month period, revenues rose by 14% year-on-year to ₹4,650 crore. The growth was fueled by innovations in the product portfolio, new brand launches, price increases, and contributions from the Stugeron portfolio. Secondary sales growth stood at 12.3% on a Moving Quarterly Total (MQT) basis and 9.7% on a Moving Annual Total (MAT) basis, outpacing overall market growth.
Emerging markets also demonstrated strong performance, with revenues rising by 32% year-on-year and 15% quarter-on-quarter to ₹900 crore in Q3FY26. For the nine-month period, revenues grew by 21% year-on-year to ₹1,960 crore. Notably, revenues from Russia reached ₹600 crore, marking a 51% year-on-year increase and a 21% sequential rise, while revenues for the nine-month period surged by 36% year-on-year to ₹2,640 crore.
Strategic Growth Initiatives
During the third quarter, Dr. Reddy’s launched 30 new products across various markets, totaling 80 launches for the first nine months of FY26. Such strategic initiatives are vital for sustaining growth, particularly in light of the competitive pressures faced in established markets.
As the company navigates these challenges, it is imperative to maintain a focus on innovation and market expansion. The commitment to launching new products and enhancing existing portfolios will be crucial for driving future revenue growth.
Conclusion
Dr. Reddy’s Laboratories has demonstrated resilience amid a challenging financial landscape, achieving commendable revenue growth while facing headwinds in profitability. The strategic focus on innovation, coupled with an expanding presence in international markets, positions the company well for future growth. As it continues to adapt to market dynamics, Dr. Reddy’s stands poised to capitalize on emerging opportunities.
- Q3 Profit: ₹1,209 crore, exceeding expectations
- Revenue Growth: 4.4% increase year-on-year
- Challenges: North American market decline due to lenalidomide sales
- European Market: Strong growth with 20% increase in Q3
- Emerging Markets: 32% revenue growth in Q3
- Product Launches: 30 new products in Q3, totaling 80 for FY26
Read more → www.cnbctv18.com